European Protein Degradation Congress 2021 | Kisaco Research

Exploring clinical developments in protein degradation and viability of proximity-based therapeutics for therapeutic benefit

2021 AGENDA RELEASED
VIRTUAL CONGRESS
21-23 September, 2021

The protein degradation field has expanded beyond just PROTACs; with developments in rational molecular glue design and the emergence of TAC variants, including abTACs and oligoTACs, it’s important to consider how proximity-based drugs can be used for therapeutic benefit using cellular activity beyond the ubiquitin-proteosome.

“This event gathered the world leaders in the protein degradation field. I thoroughly enjoyed the opportunity to get up to date on the latest approaches used by both pharma companies and academics. The setup also allowed a great opportunity to network. I will definitely be back!”

Frantz Jean-Francois, NIH

Why Attend

Protein degradation has redefined the drug discovery landscape, offering a promising solution in the quest to ‘drug the undruggable’. Whilst over the past few years this field as witnessed unprecedented growth, investment, and intrigue (around €4 billion worth, to be precise), 2021 is set to be another showstopper for targeted protein degradation with 15 compounds predicted to enter the clinic by the end of the year.

As we enter a new wave of drug discovery:

  • Explore the clinical viability of protein degraders including discussions on delivery methods, optimisation strategies and DMPK & SAR parameters
  • Learn how multispecifics that form connections between POIs and cellular machinery are expanding drug amenability of proteins in this untapped, new wave of medicine.
  • Reach “undruggable” high-hanging fruit using chemoproteomics platforms including DNA encoded libraries and covalent ligand discovery
200+
Attendees
24+
Leading Speakers
2
Days of sharing the latest developments

Poster Submission 2021

Looking to showcase your recent work to the protein degradation community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.

Poster abstract submission deadline is on 17 August 2021. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

If you have any questions please contact [email protected] 

SUBMIT YOUR POSTER HERE

Previous Attendees Include

Audience Breakdown

2021 Partners

Expertise Partners

Event Partners

What attendees say

2021 Speakers

 

Benedict Cross

Phoremost

Benedict Cross

Phoremost

Benedict Cross

Phoremost
 

Carlotta Cecchini

University of Geneva

Carlotta Cecchini

University of Geneva

Carlotta Cecchini

University of Geneva
 

Christina Woo

Harvard University

Christina Woo

Harvard University

Christina Woo

Harvard University
 

Constantine Mitsiades

DFCI

Constantine Mitsiades

DFCI

Constantine Mitsiades

DFCI
 

Daniel Nomura

Professor of Chemical Biology
UC Berkeley

Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D.

Daniel Nomura

Professor of Chemical Biology
UC Berkeley

Daniel Nomura

Professor of Chemical Biology
UC Berkeley

Dan Nomura is a professor in the Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology at the University of California, Berkeley. He is also an adjunct professor in the Department of Pharmaceutical Chemistry at UCSF. He is also the director of the Novartis-Berkeley Center for Proteomics and Chemistry Technologies. Dr. Nomura is also an editor for Cell Chemical Biology and Current Protocols in Chemical Biology. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology with Professor John Casida at UC Berkeley and was a postdoctoral fellow at The Scripps Research Institute in chemical physiology with Professor Ben Cravatt before returning to UC Berkeley as a faculty member in 2011. Among his honors are selection as a Searle Scholar, American Cancer Society Research Scholar Award, the Department of Defense Breakthroughs Award, and the Mark Foundation for Cancer Research INSPIRE award. Research in the Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to discover new disease therapies. 

 

Anthony Slavin

VP Inflammation and Immunology
Kymera Therapeutics

Anthony Slavin

VP Inflammation and Immunology
Kymera Therapeutics

Anthony Slavin

VP Inflammation and Immunology
Kymera Therapeutics
 

Elmar Wolf

University of Wurzbug

Elmar Wolf

University of Wurzbug

Elmar Wolf

University of Wurzbug
 

Fu-Sen Liang

Case Western Reserve University

Fu-Sen Liang

Case Western Reserve University

Fu-Sen Liang

Case Western Reserve University
 

Gaoqi Weng

Zhejiang University

Gaoqi Weng

Zhejiang University

Gaoqi Weng

Zhejiang University
 

Kristin Riching

Senior Scientist
Promega

Kristin received her Ph.D.

Kristin Riching

Senior Scientist
Promega

Kristin Riching

Senior Scientist
Promega

Kristin received her Ph.D. in Biomedical Engineering from the University of Wisconsin – Madison, where she studied the structural and mechanical properties of collagen fibre networks and their effects on breast cancer cell migration in invasive ductal carcinoma.  She joined Promega in 2014 as a postdoctoral researcher to study the pharmacology of ligand-dependent responses within the ErbB signalling network.   Currently, she is a Senior Scientist developing technologies and approaches for live cell characterization of protein degradation and protein interactions within the ubiquitin proteasome pathway.

 

Laura Itzhaki

Professor of Structural Pharmacology
University of Cambridge

Laura Itzhaki

Professor of Structural Pharmacology
University of Cambridge

Laura Itzhaki

Professor of Structural Pharmacology
University of Cambridge
 

Leah Fung

Biothery

Leah Fung

Biothery

Leah Fung

Biothery
 

Matthias Brand

Proxygen

Matthias Brand

Proxygen

Matthias Brand

Proxygen
 

Riccardo De Matos Simoes

DFCI

Riccardo De Matos Simoes

DFCI

Riccardo De Matos Simoes

DFCI
 

Sandra Kumper

GSK

Sandra Kumper

GSK

Sandra Kumper

GSK
 

Sara Pannilunghi

University of Geneva

Sara Pannilunghi

University of Geneva

Sara Pannilunghi

University of Geneva
 

Stina Lundgren

Principal Project Advisor
Pelago Biocsience

Stina Lundgren

Principal Project Advisor
Pelago Biocsience

Stina Lundgren

Principal Project Advisor
Pelago Biocsience
 

Thomas Hayhow

Astra Zeneca

Thomas Hayhow

Astra Zeneca

Thomas Hayhow

Astra Zeneca
 

Tom Stepherd

Captor Therapeutics

Tom Stepherd

Captor Therapeutics

Tom Stepherd

Captor Therapeutics
 

Yifat Merbl

Weizmann Institute

Yifat Merbl

Weizmann Institute

Yifat Merbl

Weizmann Institute
 

Yu Rao

Associate Professor, The Department of Pharmaceutical Chemistry and Engineering, School of Pharmaceutical Science
Tsinghua University

Yu Rao

Associate Professor, The Department of Pharmaceutical Chemistry and Engineering, School of Pharmaceutical Science
Tsinghua University

Yu Rao

Associate Professor, The Department of Pharmaceutical Chemistry and Engineering, School of Pharmaceutical Science
Tsinghua University
 

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

Zuzanna Kozicka

PhD Candidate
Friedrich Miescher Institute for Biomedical Research

I am a PhD student in the laboratory of Nicolas Thomä at the Friedrich Miescher Institute in Basel, Switzerland. I have an avid interest in molecular glue degraders and, more generally, in understanding how changes in protein interactomes can be brought about by the binding of small molecules. Prior to joining the Thomä lab, I completed my studies at the University of Edinburgh and I undertook various research projects, including one in the laboratory of Alessio Ciulli at the University of Dundee that focussed on PROTAC ‘linkerology’.

Resources

Download Resource

The Agenda

Please complete the from to receive the full agenda for 2021, including information about the key topics being covered, speakers, and why you should attend.

What you can expect from the 2021 congress:

  • 200+ participants from leading industry players within big pharma and biotech along with expert academics and service providers.
  • An open forum to share the latest in vivo and in vitro data and insights and foster collaboration. 
  • 20+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
  • 3 days of progressing translation of protein degradation probes into safe, effective therapeutics.

Download Agenda

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Ticket prices increase in

Thursday, June 3, 2021 to Friday, July 2, 2021
Super Early Bird - Academics & Research Institutes
€799 + VAT
Super Early Bird Ends Friday, 2 July 2021. Save €400.
Must be a full time academic or healthcare professional
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Thursday, June 3, 2021 to Friday, July 2, 2021
Super Early Bird - Biotechs & Pharma
€1499 + VAT
Super Early Bird ends Friday, 2 July 2021. Save €400.
Must have an active pipeline
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Thursday, June 3, 2021 to Friday, July 2, 2021
Super Early Bird - Service Providers
€1899 + VAT
Super Early Bird ends Friday, 2 July 2021. Save €600.
2 day conference pass
Networking opportunities
To increase your brand presence, contact [email protected]
Preparing registration...

highlights from previous years

Protein degradation Congress

The Virtual Experience

Top 10 benefits

- Tailor Your Agenda 

- More Audience Participation

- Improved Audience Visibility 

- On-Demand Content

- High Quality Speakers 

- More Networking Opportunities 

- Save Time & Money 

- Increased Content 

- More insights 

- Business Development Opportunities - Talk to our team to find out out more [email protected].

Platform Preview

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us